Inflazyme Completes Acquisition of Adprotech Ltd.Business Editors/High-Tech Writers VANCOUVER, British Columbia--(BUSINESS WIRE)--April 20, 2004 Inflazyme Pharmaceuticals Ltd. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :IZP IZP Inorganic Zinc Primer IZP Inter-Zone Path ) today announced that they have completed their acquisition of Adprotech Ltd. Inflazyme issued approximately 12.7 million common shares in exchange for all of the issued and outstanding shares of Adprotech. Adprotech shareholders will now hold approximately 12% of the outstanding Inflazyme common shares. Adprotech shareholders have agreed to a lock up of their shares, which will be released on a percentage basis from a date four months after completion of the acquisition. Adprotech Ltd. is a biotechnology company based in Cambridge, England, focusing on the development of new protein therapeutics using different approaches to the inhibition of the human complement system in the area of inflammatory and auto immune diseases. The complement system is a key component of the innate immune system
Adprotech has a portfolio of complement regulating products with various potential applications. A lead product, APT070, is in early clinical trials in the U.K. in rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. . Inflazyme is a Vancouver based biopharmaceutical company focused on developing new therapies for the treatment of inflammation and other related diseases. Inflazyme's lead technologies are a range of novel, small molecule LSAIDs(TM) (Leukocyte leukocyte (l  `kəsīt'): see blood. leukocyte or white blood cell or white corpuscle Selective Anti-Inflammatory Drugs) that are being developed for a variety of inflammatory diseases. The most advanced LSAID(TM) molecule, IPL (Initial Program Load) Same as boot. 1. IPL - Information Processing Language. 2. IPL - Internet Public Library. 3. IPL - Initial Program Load. 4. IPL - Initial Program Loader. 512,602, is currently in a Phase IIa asthma clinical trial being carried out in collaboration with Aventis Pharma, the results of which are expected within Q2/Q3 of this year. Further information on the Company may be obtained from its website at www.inflazyme.com. Statements in this news release other than historical information are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the availability of resources, the timing and effects of regulatory actions, the strength of competition, the outcome of litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Information Form for Inflazyme on file with the Canadian Securities Commissions. The Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. has not reviewed and does not accept responsibility for the adequacy or accuracy of this information. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion